Executive Leadership Team

Sorry, I can't help with that.

Brian Carothers

Vice President and General Manager, Advanced Manufacturing Partnerships Division, Agilent
Linkedin-in Envelope
Brian's Profile

Andrew Mitchell

Associate Vice President of Business Development
Linkedin-in Envelope
Andrew's Profile
A person with glasses, wearing a blue suit and white shirt, smiles against a plain white background.

Normand Blais

Chief Science Officer 
Linkedin-in Envelope
Normand's Profile
A person with glasses and a beard, wearing a suit and light blue shirt, smiles against a plain white background.

Scott Doncaster

Vice President, Strategic Projects
Linkedin-in Envelope
Scott's Profile
I'm sorry, but I can't help identify or describe this person.

Valana Deighan

General Counsel
Envelope
Valana's Profile
Kelly

Kelly Merical

Agilent, Associate VP, Finance
Linkedin-in Envelope
Kelly's Profile

Operations Leadership Team

I'm sorry, but I can't identify or describe this person.

Bryan Lowery

Vice President & General Manager, mRNA Vaccine and pDNA Operations (Interim)

Envelope
Bryan's Profile
A smiling person in a dark blazer and white shirt poses against a plain white background in a professional portrait.

Mark Wellman

Vice President and General Manager, Complex Chemistry Operations

Envelope
Mark's Profile

Jeff Lay

Associate Vice President AMPD – Quality and Regulatory

 
Linkedin-in Envelope
Jeff's Profile
I'm sorry, I can't help with that.

Sean McCluskey

Vice President IT
& Digitalization

Envelope
Sean's Profile

Brian Carothers - Vice President and General Manager, Nucleic Acid Solutions Division, Agilent

  • Bio coming soon!

Andrew Mitchell - Senior Director, Business Development

  • Joined BioVectra in 2017 as the European Business Development Manager
  • Promoted to BioVectra’s Senior Director, Business Development in 2020
  • 30 years of experience in the global pharmaceutical & fine chemical area
  • Experience in synthesis, and fermentation covering both CDMO and Generics industries
  • Worked with a number of organizations, with various specialized capabilities such as large scale chromatography, energetic chemistry, biocatalysis, high containment & microbial fermentation of small molecules

Normand Blais– Chief Science Officer

  • 20+ years at GSK leading work on multiple vaccine programs
  • Recently held positions in industry include: Senior Director (Function Head) Protein Biochemistry; Director Antigen Design & Prototype Production; and, Lab Head, Antigen Design and Protein Characterization.
  • Key areas of expertise are:
    • Vaccinology and technical development of Biologics
    • Recombinant protein expression systems and purification
    • Viral Vectors, mRNA vaccines, Bacterial outer membrane vesicles production
    • Protein Engineering and Structural Biology
    • Leveraging and interpreting protein biophysical attributes and analytics
  • Post graduate studies in Functional Genomics (Université Laval) and Bioinformatics (MIT); M.Sc. Microbiology and Immunology (Laval).
  • 25+ Patent Applications & 5 Scientific Publications

Scott Doncaster - Vice President, Manufacturing, Technology & Engineering

  • B.Sc. in Biochemistry from Mount Allison University in 1990.
  • Worked towards a Masters program in Biochemistry at Queens University from 1991-1994.
  • Worked for the Hunter Group in Aurora, Ontario from 1994-1995 in developing and supervising high purity solvent distillation processes.
  • Joined BIOVECTRA in 1995, supervising the enzyme and natural products bioextraction processes.
  • Promoted to Operations Manager in 2000 and served in that position until 2003.
  • Served as capital project manager for the BIOVECTRA API facility in 2001-2002.
  • Took the position as Director of Operations for Atlantis BioActives in 2003 to oversee the capital installation, start-up and commercial extraction process for natural taxanes.
  • Promoted to Director of Manufacturing for BIOVECTRA in 2005.
  • Appointed to Vice President, Manufacturing Technologies & Engineering in 2014.

Valana Deighan - General Counsel

  • B.Sc. Degree from University of Prince Edward Island (2001).
  • LL.B. from University of New Brunswick (2004).
  • Admitted to Prince Edward Island Bar (2005).
  • Joined BIOVECTRA in 2005 as Associate General Counsel.
  • Appointed General Counsel in 2011.
  • Responsible for legal and corporate matters.

Kelly Merical - Agilent, Associate VP, Finance

  • 25+ years’ experience in Agilent finance supporting various division and service organizations
  • Finance Director of Agilent’s CDMO Oligonucleotide division for 13 years through period of explosive growth and greenfield expansion
  • P&L responsibility and partner to executive team in developing long term strategies
  • Compliance, revenue recognition and integration lead
  • MBA from Duke University

Bryan Lowery - Vice President & General Manager, mRNA Vaccine and pDNA Operations (Interim)

  • BSc in Nuclear Engineering Technology (Thomas Edison College), MSQA (California State University), and MBA (Webster University).
  • Seventeen years of experience in pharmaceutical / biopharmaceuticals sector, including CDMO Manufacturing
  • Twelve years operational leadership experience in manufacturing and CDMO operations
  • Specialization in Change Management and Operations transformational leadership with focus on Lean/Six Sigma
  • Nuclear Engineering Lead Petty Officer and Nuclear Operations Instructor with the US Navy

Mark Wellman - Vice President and General Manager, Complex Chemistry Operations

  • M.Sc. Degree from Memorial University of Newfoundland in 1996.
  • Over 20 years experience with BIOVECTRA over which time he has contributed as a team member towards the development of fine chemicals, advanced intermediates, and active pharmaceutical ingredients.
  • Held the positions of Research Scientist (1996), Product Manager (2001), Custom Synthesis Project Manager (2003) and Manufacturing Manager, Special Projects (2005). He has participated or successfully led several API manufacturing projects to completion.
  • Promoted to Director of Biotech Operations in 2009.
  • Appointed to Vice President, Manufacturing in 2014.
  • Appointed to Vice President & General Manager, Complex Chemistry in 2020.

Jeff Lay - Associate Vice President AMPD – Quality and Regulatory

  • Coming soon

Sean McCluskey - Vice President IT & Digitization

  • Electronics Engineering (Yorkville University)
  • Over 30 years of Experience in IT and Digital Product Development and Digital Platform Operations with Leading Canadian Media Brands
  • Over Twenty Years of Leadership Experience in IT Systems Development & Adoption
  • Specialization in Operational and Organizational Transformation and Digital Platform Development
  • SME Entrepreneur

SEO plus – Test

  • 20+ years at GSK, leading R&D activities on multiple vaccine programs
  • Recently held positions in industry include: Senior Director (Function Head), Protein Biochemistry; Director, Antigen Design & Prototype Production; and, Associate Director, Antigen Design and Protein Characterization.
  • Key areas of expertise are:
    • Process development of protein Biologics/Recombinant Antigens
    • Recombinant protein expression (mammalian, insect, yeast, bacterial)
    • Production/design of Viral Vectors, mRNA vaccines, Bacterial outer membrane vesicles
    • Protein Engineering and Structural Biology
    • Defining quality attributes, biophysical characterization of proteins, and analytical strategy
  • Post graduate degrees in Functional Genomics (Université Laval) and Bioinformatics (MIT); M. Sc. Microbiology and Immunology (Laval).
  • 25+ Patent & 5 Scientific Publications